find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
23
Clinical Trials
Leukemia
Phase III
Enrolling
nct/study# NCT06479135 / KRT-232-115
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) That have a Suboptimal Response to Ruxolitinib.
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / MYELOFIBROSIS-TRANSPLANT
Clinical, Transplant, and Molecular Predictors of Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
Learn More
Leukemia
Phase II
Enrolling
nct/study# NCT06384261 / OV-AML-1231
A MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 2 STUDY OF VENETOCLAX AND AZACITIDINE PLUS CUSATUZUMAB VERSUS VENETOCLAX AND AZACITIDINE ALONE IN NEWLY DIAGNOSED AML PATIENTS WHO ARE NOT CANDIDATES FOR INTENSIVE THERAPY
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / QUIZ-REAL-WORLD-PROJECT
Real-world comparative effectiveness and safety of FLT3 inhibitors combined with induction chemotherapy in acute myeloid leukemia
Learn More
Leukemia
N/A
Enrolling
nct/study# NCT06456463 / STML-401-0423
STML-401-0423 A Phase II Multicenter Open-Label Trial of Tagraxofusp (TAG) in Combination with Venetoclax and Azacitadine (VEN/AZA) in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia (AML) who are Ineligible for Intensive Chemotherapy
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / VENETOCLAX-AML
Effect of Adding Venetoclax to Intensive Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.